BioCorRx (BICX) Common Equity (2016 - 2025)
Historic Common Equity for BioCorRx (BICX) over the last 17 years, with Q3 2025 value amounting to -$13.5 million.
- BioCorRx's Common Equity fell 1234.19% to -$13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.5 million, marking a year-over-year decrease of 1234.19%. This contributed to the annual value of -$12.4 million for FY2024, which is 22414.17% down from last year.
- Latest data reveals that BioCorRx reported Common Equity of -$13.5 million as of Q3 2025, which was down 1234.19% from -$13.0 million recorded in Q2 2025.
- In the past 5 years, BioCorRx's Common Equity registered a high of $10.0 million during Q4 2023, and its lowest value of -$13.5 million during Q3 2025.
- Its 5-year average for Common Equity is -$8.0 million, with a median of -$8.7 million in 2023.
- Per our database at Business Quant, BioCorRx's Common Equity skyrocketed by 22134.66% in 2023 and then plummeted by 22414.17% in 2024.
- BioCorRx's Common Equity (Quarter) stood at -$7.0 million in 2021, then dropped by 17.82% to -$8.2 million in 2022, then skyrocketed by 221.35% to $10.0 million in 2023, then crashed by 224.14% to -$12.4 million in 2024, then fell by 9.14% to -$13.5 million in 2025.
- Its Common Equity stands at -$13.5 million for Q3 2025, versus -$13.0 million for Q2 2025 and -$11.8 million for Q1 2025.